- Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer
[作者:Goodwin, PJ; Ennis, M; Pritchard, KI; Koo, J; Hood, N,期刊:Journal of clinical oncology, 页码:3757-3763 , 文章类型: Article,,卷期:2009年27-23]
- PurposeVitamin D has been linked to breast cancer risk, but prognostic effects are unknown. Such effects are biologically plausible given the presence of vitamin D receptors in breast cancer cells, which act as nuclear t...
- Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
[作者:Kriege, M; Seynaeve, C; Meijers-Heijboer, H; Collee, JM; Menke-Pluymers, MBE; Bartels, CCM; Tilanus-Linthorst, MMA; Blom, J; Huijskens, E; Jager, A; van den Ouweland, A; van Geel, B; Hooning, MJ; Brekelmans, CTM; Klijn, JGM,期刊:Journal of clinical oncology, 页码:3764-3771 , 文章类型: Article,,卷期:2009年27-23]
- PurposePreclinical as well as a few small retrospective, neoadjuvant studies suggest that breast cancer (cells) without functional BRCA1 or BRCA2 protein have an increased sensitivity to some chemotherapeutic agents caus...
- Patients With Merkel Cell Carcinoma Tumors <= 1.0 cm in Diameter Are Unlikely to Harbor Regional Lymph Node Metastasis
[作者:Stokes, JB; Graw, KS; Dengel, LT; Swenson, BR; Bauer, TW; Slingluff, CL; Ledesma, EJ,期刊:Journal of clinical oncology, 页码:3772-3777 , 文章类型: Article,,卷期:2009年27-23]
- PurposeMerkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy. Current recommendations include offering regional lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complet...
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
[作者:Poplin, E; Feng, Y; Berlin, J; Rothenberg, ML; Hochster, H; Mitchell, E; Alberts, S; O'Dwyer, P; Haller, D; Catalano, P; Cella, D; Benson, AB,期刊:Journal of clinical oncology, 页码:3778-3785 , 文章类型: Article,,卷期:2009年27-23]
- PurposeSingle-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare o...
- Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
[作者:Starling, N; Rao, S; Cunningham, D; Iveson, T; Nicolson, M; Coxon, F; Middleton, G; Daniel, F; Oates, J; Norman, AR,期刊:Journal of clinical oncology, 页码:3786-3793 , 文章类型: Article,,卷期:2009年27-23]
- PurposeData concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are undergoing chemotherapy are limited.Patients and MethodsThis was a pr...
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
[作者:Schlumberger, MJ; Elisei, R; Bastholt, L; Wirth, LJ; Martins, RG; Locati, LD; Jarzab, B; Pacini, F; Daumerie, C; Droz, JP; Eschenberg, MJ; Sun, YN; Juan, T; Stepan, DE; Sherman, SI,期刊:Journal of clinical oncology, 页码:3794-3801 , 文章类型: Article,,卷期:2009年27-23]
- Purpose This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth fac...
- Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center
[作者:Blayney, DW; McNiff, K; Hanauer, D; Miela, G; Markstrom, D; Neuss, M,期刊:Journal of clinical oncology, 页码:3802-3807 , 文章类型: Article,,卷期:2009年27-23]
- PurposeThe Quality Oncology Practice Initiative (QOPI) is a voluntary program developed by the American Society of Clinical Oncology (ASCO) to aid oncology practices in quality self-assessment. Few academic cancer center...
- Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia
[作者:Shanafelt, TD; Call, TG; Zent, CS; LaPlant, B; Bowen, DA; Roos, M; Secreto, CR; Ghosh, AK; Kabat, BF; Lee, MJ; Yang, CS; Jelinek, DF; Erlichman, C; Kay, NE,期刊:Journal of clinical oncology, 页码:3808-3814 , 文章类型: Article,,卷期:2009年27-23]
- PurposeTo define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with chronic lymphocytic leukemia (CLL).Patients and MethodsPreviously untreated patients with asymptomatic ...
- Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients
[作者:Diepstra, A; van Imhoff, GW; Schaapveld, M; Karim-Kos, H; van den Berg, A; Vellenga, E; Poppema, S,期刊:Journal of clinical oncology, 页码:3815-3821 , 文章类型: Article,,卷期:2009年27-23]
- PurposeIn classical Hodgkin's lymphoma (cHL), the impact of tumor cell Epstein-Barr virus (EBV) status on clinical outcome is controversial.Patients and MethodsWe assessed failure-free survival (FFS) and relative surviva...
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
[作者:Hess, G; Herbrecht, R; Romaguera, J; Verhoef, G; Crump, M; Gisselbrecht, C; Laurell, A; Offner, F; Strahs, A; Berkenblit, A; Hanushevsky, O; Clancy, J; Hewes, B; Moore, L; Coiffier, B,期刊:Journal of clinical oncology, 页码:3822-3829 , 文章类型: Article,,卷期:2009年27-23]
- PurposeTemsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investig...
- Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
[作者:Treon, SP; Ioakimidis, L; Soumerai, JD; Patterson, CJ; Sheehy, P; Nelson, M; Willen, M; Matous, J; Mattern, J; Diener, JG; Keogh, GP; Myers, TJ; Boral, A; Birner, A; Esseltine, DL; Ghobrial, IM,期刊:Journal of clinical oncology, 页码:3830-3835 , 文章类型: Article,,卷期:2009年27-23]
- PurposeWe examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).Patients and MethodsA cycle of therapy consisted of bortezomib ...
- Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
[作者:Schiller, JH; Larson, T; Ou, SHI; Limentani, S; Sandler, A; Vokes, E; Kim, S; Liau, K; Bycott, P; Olszanski, AJ; von Pawel, J,期刊:Journal of clinical oncology, 页码:3836-3841 , 文章类型: Article,,卷期:2009年27-23]
- PurposeThis phase II study evaluated efficacy and safety of single-agent axitinib, an oral, potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, in patients with advanced no...
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
[作者:Steensma, DP; Baer, MR; Slack, JL; Buckstein, R; Godley, LA; Garcia-Manero, G; Albitar, M; Larsen, JS; Arora, S; Cullen, MT; Kantarjian, H,期刊:Journal of clinical oncology, 页码:3842-3848 , 文章类型: Article,,卷期:2009年27-23]
- PurposeDecitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m(2) administer...
|